R Edelstein
About
In The Last Decade
R Edelstein
23 papers receiving 479 citations
Peers
Comparison fields: 5 of 85
- Pulmonary and Respiratory Medicine 183
- Oncology 149
- Immunology 132
- Endocrinology, Diabetes and Metabolism 94
- Molecular Biology 90
Countries citing papers authored by R Edelstein
This map shows the geographic impact of R Edelstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R Edelstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R Edelstein more than expected).
Fields of papers citing papers by R Edelstein
This network shows the impact of papers produced by R Edelstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R Edelstein. The network helps show where R Edelstein may publish in the future.
Co-authorship network of co-authors of R Edelstein
This figure shows the co-authorship network connecting the top 25 collaborators of R Edelstein. A scholar is included among the top collaborators of R Edelstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R Edelstein. R Edelstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Very early ACE inhibition reduces progressive left ventricular dilation when tPA fails to establish early reperfusion during acute anterior myocardial infarction | 3 |
| 2 | 159 | |
| 3 | The effect of RU 41.740, an immune modulating compound, in the prevention of acute exacerbations in patients with chronic bronchitis. | 16 |
| 4 | 4 | |
| 5 | In vivo nonspecific macrophage chemotaxis in cancer patients and its correlation with extent of disease, regional lymph node status, and disease-free survival. | 14 |
| 6 | 49 | |
| 7 | 3 | |
| 8 | [Immunosuppressive effects of acute phase reactant proteins. Physiopathological role in cancer patients (author's transl)]. | 4 |
| 9 | 6 | |
| 10 | Testing the monocyte-macrophage system in human cancer. | 9 |
| 11 | Immunological and plasma protein changes in cancer patients following a single plasmapheresis. | 7 |
| 12 | In vivo and in vitro studies on nonspecific blocking factors of host origin in cancer patients. Role of plasma exchange as an immunotherapeutic modality. | 20 |
| 13 | Immunochemotherapy in 34 cases of oat cell carcinoma of the lung with 19 complete responses. | 20 |
| 14 | 59 | |
| 15 | 8 | |
| 16 | 55 | |
| 17 | Effect of intranodular B.C.G. in 22 melanoma patients. | 9 |
| 18 | 17 | |
| 19 | 47 | |
| 20 | 42 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.